NCT07265674 2026-04-09
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT03110510 2022-06-15
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Withdrawn
NCT03778593 2021-02-04
FOLFIRINOX for 2nd-line Treatment of BTC
Dong-A University Hospital
Phase 2 Completed
NCT00948935 2020-03-11
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02558959 2018-02-13
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Zhejiang University
Phase 2 Completed
NCT02720601 2018-01-25
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT01859728 2018-01-18
GAMBIT
Barretos Cancer Hospital
Phase 2 Unknown
NCT02527824 2017-08-23
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
Hallym University Medical Center
Phase 2 Unknown
NCT01494363 2011-12-19
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Soon Chun Hyang University
Phase 2 Unknown
NCT00832689 2011-03-28
Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
Yonsei University
Phase 2 Completed